As of Aug 18
| -2.65 / -0.93%|
The 27 analysts offering 12-month price forecasts for Biogen have a median target of 329.00, with a high estimate of 442.00 and a low estimate of 274.00. The median estimate represents a +16.76% increase from the last price of 281.77.
The current consensus among 30 polled investment analysts is to Buy stock in Biogen. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.